Innocoll (INNL) began trading on the NASDAQ on 25 July 2014

The Irish drug company makes after-surgery pain treatment and medicine for diabetic foot infections. It raised $58.5 million after pricing 6.5 million American depositary shares at $9 per ADS. It previously expected to raise more money, between $69.6 million and $80.3 million, in a larger offering of shares. Innocoll plans to use the cash it raised to develop its treatments and increase its manufacturing infrastructure. Its shares, which are trading on the Nasdaq exchange under the symbol "INNL," closed flat at $9. During trading hours, the stock fell as low as $8.58 and rose as high as $9.51.